Semax is a synthetic neuroprotective peptide primarily used in stroke research and the regulation of central nervous system functions. As an analogue of the adrenocorticotropic hormone (ACTH) fragment, it penetrates the blood-brain barrier through a unique mechanism, promoting neural regeneration and repair. In experimental models, Semax has shown potential in improving cerebral blood flow and regulating neurotransmitter activity, but its clinical applications still require further validation.
I. Structure and Biological Activity
Semax is a synthetic analogue of the ACTH (4-10) fragment, with its chemical structure modified to remove hormonal activity while retaining neuroregulatory functions. Its derivative, Semax acetate (CAS 2828433-33-4), has become the main form used in research due to enhanced stability and improved bioavailability. This modification allows it to rapidly pass through the blood-brain barrier after intranasal administration, with effects lasting up to 24 hours after a single dose, making it suitable for acute neural injury scenarios.
II. Mechanism of Action and Neuroprotective Effects
Semax exerts its effects through dual pathways:
Promoting Neurotrophic Factor Expression: Semax upregulates the levels of brain-derived neurotrophic factor (BDNF) and its receptor TrkB in the hippocampus, directly supporting neuronal survival and synaptic plasticity, and accelerating the reconstruction of neural circuits after injury.
Regulating Neurotransmitter Systems: It activates serotonin and dopamine pathways, improving mood and cognitive functions. Studies have shown that it can counteract cognitive damage induced by chronic stress and enhance motor activity induced by D-amphetamine, suggesting its ability to regulate neuronal excitability in a bidirectional manner.
III. Application in Stroke Research
As a candidate drug for ischemic brain injury, Semax acetate has shown threefold therapeutic potential:
Improving Cerebral Blood Flow: It reduces the expansion of the ischemic penumbra through vascular regulation.
Reducing Secondary Damage: It inhibits oxidative stress and inflammatory responses, lowering the risk of cerebral edema.
Promoting Functional Recovery: It stimulates neural stem cell differentiation and axonal regeneration. Animal models have shown that early administration can significantly reduce infarct size and improve motor function scores.
IV. Research Status and Challenges
Despite promising preclinical data, Semax has not yet received FDA approval, and its safety and long-term efficacy require validation through large-scale clinical trials. Current research focuses on optimizing dosing regimens (such as dose-response relationships) and expanding indications (such as for neurodegenerative diseases). Additionally, its differential effects in various stress models suggest a need for individualized treatment strategies. Future research will need to incorporate biomarkers to accurately select populations that would benefit from Semax.
If you want to buy Semax Peptide Vial and would like to learn more, please feel free to contact Xi'an Ruichi. We look forward to hearing from you.
Email: Jenny@ruichibio.com
Reference:https://www.ruichibio.com/lyophilized-peptide/semax-peptide-vial.html